SCRS turns site feedback into a measurable clinical trial performance score
The Society for Clinical Research Sites has launched Eagle Insights Dashboard, a data intelligence platform designed to quantify how sponsors and CROs perform in the relationships that influence trial execution most. In practical terms, the tool converts site feedback into a score that reflects whether a research organization is functioning as a true partner or merely moving through the mechanics of study conduct. For an industry that depends on site trust, that shift from anecdote to measurement is consequential.
The dashboard aggregates ratings across several categories tied directly to trial feasibility and site burden: study start-up and planning, business development, contract language, communication and advocacy, representative patient populations, and technology, among others. Those domains are not administrative side issues. They shape whether a protocol gets activated efficiently, whether a site remains engaged after enrollment pressure builds, and whether investigators believe the sponsor understands the realities of frontline research delivery.
A single stalled contract or opaque communication process can delay activation as surely as a poor protocol design can slow accrual.
SCRS says sponsors and CROs will be able to use the feedback to identify engagement gaps early, compare performance against peers, and make more informed decisions about investment and process changes. That matters because site dissatisfaction often accumulates quietly before it surfaces in measurable delays, strained enrollment, or lost participation in future studies. A dashboard that captures the signals early creates a chance to intervene before those frictions harden into reputational damage.
Benchmarking site relationships as a business and operational metric
The platform is built around the idea that sponsor-site relationships can be assessed with the same rigor as other operational metrics in clinical development. Each score reflects a composite view of how a sponsor or CRO is perceived by sites on the dimensions that affect daily trial work. Instead of relying on internal assumptions about partnership quality, organizations can compare their standing against peers and competitors using objective feedback from the site community.
Jimmy Bechtel, chief site success officer at SCRS, framed the problem plainly: every sponsor and CRO wants to be a partner of choice, but few have had a reliable method to determine whether that is actually true. The dashboard is meant to fill that gap. It surfaces where relationships are working, where they are not, and how an organization stacks up against others in the field. For trial operators, those comparisons can influence everything from vendor selection and country strategy to resourcing decisions and site engagement models.
The clinical importance extends beyond organizational optics. Sites that feel heard and supported are more likely to respond quickly to feasibility requests, maintain communication through startup bottlenecks, and sustain participation across multicenter programs. A better relationship framework can also affect how sites view protocol amendments, data queries, and workflow changes once a study is underway. In a field where execution problems often masquerade as isolated local issues, a structured feedback system can reveal whether the root cause is actually systemic.
2025 to 2026 data will expand the platform’s trend analysis
By November, the dashboard will include data from 2025 to 2026, allowing organizations to track trends over time rather than viewing site feedback as a one-off snapshot. Longitudinal data changes the utility of the platform in a meaningful way. A single score can describe the present; a sequence of scores can show whether an organization is improving, plateauing, or slipping in the eyes of the sites it depends on.
That matters in clinical research because site relationships are not static. A sponsor can earn goodwill through a smooth startup process and then lose it through poor communication during amendments or inconsistent contract negotiations. Trend analysis offers a way to catch those reversals. It also gives companies a cleaner basis for deciding whether process changes are truly working or simply creating the appearance of progress.
SCRS described itself as the only global organization dedicated exclusively to representing the interests of clinical research sites, and the launch fits squarely within that remit. The platform places site experience at the center of performance evaluation rather than treating it as a soft, secondary consideration. In a sector that often talks about patient access and accelerated development, the dashboard reasserts a basic operational truth: studies run through sites, and sites respond to how they are treated.
One leading global biopharmaceutical company has already adopted the dashboard as part of its commitment to strengthening site relationships. That early use suggests the measure is intended for more than passive reporting. If organizations begin using the data to revise internal practices, the platform could influence how sponsors and CROs train teams, structure site communication, and prioritize operational fixes.
Objective feedback may reshape sponsor and CRO behavior
The deeper value of the dashboard lies in replacing assumption with evidence. Many organizations believe they are responsive, collaborative, and easy to work with. Sites may tell a different story. By converting those perceptions into quantifiable scores, the platform introduces accountability into an area that has often depended on informal impressions and selective feedback.
This could have downstream effects on how clinical trial ecosystems function. Sponsors that consistently score poorly on communication or contract language may need to confront delays that stem not from scientific complexity but from preventable process failures. CROs may be forced to compare their site relationships with competitors in a way that exposes weaknesses they have not fully recognized. Over time, those insights could drive more disciplined site engagement strategies and more realistic investment in support infrastructure.
The dashboard also speaks to a persistent tension in clinical research: the industry depends on sites for execution, yet site experience is frequently measured indirectly, inconsistently, or not at all. A dedicated score based on site feedback makes that experience visible. Visibility does not solve every operational problem, but it gives sponsors and CROs a starting point that is grounded in evidence rather than self-assessment.
For now, the platform is being positioned as a tool for stronger relationships, better benchmarking, and more informed decision-making. The open question is how quickly organizations will use the data to alter behavior rather than simply admire the metrics. Without that follow-through, even the most detailed dashboard becomes another report that confirms what sites have already been saying for years.